CN102379970A - TCM composition used for treating IBS - Google Patents
TCM composition used for treating IBS Download PDFInfo
- Publication number
- CN102379970A CN102379970A CN2011103363802A CN201110336380A CN102379970A CN 102379970 A CN102379970 A CN 102379970A CN 2011103363802 A CN2011103363802 A CN 2011103363802A CN 201110336380 A CN201110336380 A CN 201110336380A CN 102379970 A CN102379970 A CN 102379970A
- Authority
- CN
- China
- Prior art keywords
- ibs
- spleen
- liver
- fire
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of treating IBS (irritable bowel syndrome) by TCM (Traditional Chinese Medicine), and particularly discloses a TCM composition prepared through specific components and proportion and used for treating IBS. The TCM composition is an oral medicine prepared through the following components by weight ratio: 100 prepared rhizome of rehmannia, 100 field dodder, 60 Coptidis rhizoma, 300 paeony, 120 parsnip, 60 cicada ecdysis, and 150 wild buckwheat rhizome. The invention holds the concepts of restoring normal coordination between heart and kidney, and regulating the function of liver and spleen. The prepared rhizome of rehmannia and the field dodder, which serve as monarch drugs, can supplement kidney water to aid internal heat; the Coptidis rhizoma serving as ministerial drug can clear stagnated fire in heart and lead the stagnated fire to reach the kidney water; the paeony which is used for soothing liver and spleen, and the parsnip and the cicada ecdysis which are used for expelling wind to relieve convulsion and regulate liver and spleen, serve as adjuvants; and the wild buckwheat rhizome serving as the conductant drug can not only clear lung fire, but also manage large intestine which can be normal as long as the lung fire is cleared, and lead all the components to reach the large intestine. The TCM composition is also effective for both diarrhea type and constipation type IBS, aims to improve high sensitivity of IBS viscus, and overcomes the disadvantage of the conventional TCM composition which is only effective to a single type of IBS such as diarrhea type IBS.
Description
[technical field]
The invention belongs to the field of treatment by Chinese herbs irritable bowel syndrome, the Chinese medicine composition that especially uses specific composition and proportioning to process is treated irritable bowel syndrome.
[background technology]
(irritable bowel syndrome is with stomachache or abdominal discomfort IBS) to irritable bowel syndrome, changes into the functional intestinal tract disease of characteristic with defecate character change and bowl evacuation habit.Irritable bowel syndrome is a chronic disease from Chinese medicine, falls ill March at least in 1 year, previously the Chinese traditional treatment irritable bowel syndrome; How to start with from soothing liver and strengthening spleen, thus many be main plus-minus with the tongxieyao formula, it is considered herein that the irritable bowel syndrome pathogenesis is a kidney usually involved in chronic disease; And kidney is Kan Gong, and viscus attributed to water and fire is so need the kidney invigorating fire (sun) with warm spleen soil; The kidney invigorating water (the moon) is with Ji heart-fire liver nourishing wood; No matter clinical manifestation still is that the irritable bowel syndrome of constipation is due to " dysfunction of the spleen in transportation " for diarrhoea, and " liver Wood restricts earth, stagnation of liver-QI with deficiency of the spleen " be the pathogenesis key; The external presentation that is irritable bowel syndrome is " stagnation of liver-QI with deficiency of the spleen ", and its inward nature is " disarmony between the heart and kidney ".So proposing " disarmony between the heart and kidney, stagnation of liver-QI with deficiency of the spleen " is pathogenesis, " restoring normal coordination between the heart and kidney, regulating the liver and spleen " is the rule of treatment.The organic conception " coordination between the heart and kidney opinion " of Chinese medicine composition utilization traditional medicine of the present invention; The whole regulation and control model of itself and modern medicine " neuroimmunoendocrinology network theory " is organically combined; Reach the kidney invigorating fire and give birth to spleen soil, the kidney invigorating water Ji heart-fire, the effect of restoring normal coordination between the heart and kidney is in harmonious proportion the whole body internal organs; The immunity homeostasis, thus reach the effect of treating IBS.
[summary of the invention]
Technical problem to be solved by this invention is utilization tcm theory and modern neuroimmunoendocrinology network theory, selects specific Chinese medicine composition to treat irritable bowel syndrome.
For overcoming the above problems, the present invention takes following technical scheme:
By weight getting 100 parts of Radix Rehmanniae Preparata, 100 parts of Semen Cuscutae, 60 parts of Rhizoma Coptidis, 300 parts of Radix Paeoniaes, windproof 120 parts, 60 parts of Periostracum Cicadaes, Rhizoma Fagopyri Dibotryis is processed oral drugs for 150 parts.
The present invention is a principle of treatment with " restoring normal coordination between the heart and kidney, regulating the liver and spleen ", and wherein Radix Rehmanniae Preparata, Semen Cuscutae the kidney invigorating water are monarch drug with the Ji heart-fire altogether; The stagnated fire that Rhizoma Coptidis clears away heart-fire also makes it to assign kidney water, is ministerial drug; The easypro spleen of the diffusing liver of Radix Paeoniae, windproof, Periostracum Cicadae expelling wind to relieve convulsion with regulating the liver and spleen, is an adjuvant drug altogether; Rhizoma Fagopyri Dibotryis supernatant lung-fire, following department large intestine, lung-heat be the large intestine peace clearly then, draws all medicines to large intestine, is messenger drug; Full side plays the merit of " restoring normal coordination between the heart and kidney, regulating the liver and spleen " altogether.Clinical application is all effective to the irritable bowel syndrome of two types of diarrhea-type, constipation types etc., and it is main only to single type such as the effective drawback of diarrhea type irritable bowel syndrome to have overcome present Chinese medicine compound.
[specific embodiment]
Embodiment
1 materials and methods
1.1 material
1.1.1 laboratory animal Sprague-Dawley rat must be provided by triumphant laboratory animal company limited by west, Shanghai pul; Quality certification SCXK (Shanghai) 2008-0016; And by the nursing of Jiangsu Prov. Research Inst. Traditional Chinese Medical Experimental Animal Center cleaning level receptacle; Temperature is indoor 22～26 ℃, natural lighting, ad lib, water.
1.1.2 experiment medicine Chinese medicine composition of the present invention is by forming by weight 100 parts of Radix Rehmanniae Preparata, 100 parts of Semen Cuscutae, 60 portions of Rhizoma Coptidis, 300 portions of Radix Paeoniaes, 120 portions of windproof, 60 portions of Periostracum Cicadaes and 150 parts of Rhizoma Fagopyri Dibotryiss; More than each single medicinal material be and exempt to fry in shallow oil Chinese medicine granules; Provided by Jiangyin Tian Jiang pharmaceutical factory, lot number is respectively: 1011141,1011163,1009081,1010036,1011026,1005141.Face with preceding and be made into 1.46g/ml solution with distilled water.Positive control drug is a Trimebutine Maleate, specification: 0.1/, and to pacify special pharmaceutical factory by Shanxi and produce, lot number is 20100501, faces with preceding to be made into 0.003g/ml solution with distilled water.(dose is promptly pressed 60kg/200g people Mus conversion coefficient W=6.25 and is calculated dose,equivalent according to the computational methods of animal experiment study dose,equivalent)
1.2 method
1.2.1 the modeling of AL-Chaer method is adopted in the animal modeling.After the pregnant Mus of Sprague-Dawley is bought back, raise separately and treat rat production, and the record date of manufacture.Accepted percutaneous transluminal coronary angioplasty sacculus colon stimulation on the 8th, 10,12 day in young male rat birth back, pressure is 60mmHg, continues 1min, every day 1 time, totally 3 times; Matched group: anal inserts balloon catheter, but does not expand.
1.2.2 grouping is divided into 6 groups with administration with 72 neonate rats at random, is divided into the high, medium and low dose groups of Chinese medicine composition of the present invention, positive drug matched group, model group and blank group, every group each 12.Rat is in birth back beginning in the 60th day gastric infusion, and the high, medium and low dose groups of Chinese medicine composition of the present invention is irritated respectively to 2ml, 1ml, 0.5ml by every 100g body weight; Positive drug (Trimebutine Maleate): 2ml/100g; Model group and blank group all give the 2ml/100g normal saline, every day 2 times, irritate stomach and continue 10 days.
1.2.3 returning, observation index and method stomach wall remove reflection experiment (abdominal withdrawal reflex; AWR), i.e. knot rectum balloon expandable (the colorectal distension under the different pressures is carried out in abdominal muscle rebound reflex sxemiquantitative scoring; CRD); Be used to assess visceral sensitivity and change, the internal organs motor reaction that CRD causes can quantize and repeat, and is the reliability index of estimating Encelialgia.After rat oral gavage finished, fasting 12 hours was placed on rat in the homemade clear glass cage, and rat can only seesaw in this cage, can not turn round.Treat that rat adapts to the back and inserts sacculus by anus, insert about 6cm～8cm, with adhesive plaster conduit and rat tails are bound with fixation balloon, the injection air gives different pressures in sacculus stimulates.Respectively 10,20,40,60, observe the abdominal muscle rebound reflex of rat under the 80mmHg pressure to the rectum balloon expandable; Each proctectasia continues 20s; Observe simultaneously rat to different pressures down due to the reaction of proctectasia, according to its reacting record sxemiquantitative behavioristics scoring.Write down the each expansion under different pressures of internal rectum sacculus simultaneously and continue rat abdominal muscle number of contractions in the 3min, each 30min at interval.Each force value detects 3 times, averages and marks, and the AWR scoring is high more, explains that visceral sensitivity is high more.
1.2.4 the criterion rat does not have ethological reaction during to ectocolon, counts 0 fen.Health transfixion during ectocolon, head movement reduces, and is the initial perception threshold, counts 1 fen.Abdominal muscles shrinks during ectocolon, is uncomfortable threshold value but abdominal muscle is not lifted away from desktop, counts 2 fens.Abdominal muscle shrinks and is lifted away from desktop during ectocolon, is pain threshold, counts 3 fens.Pelvis lifts during ectocolon, and it is arc that health is, and for maximum tolerance threshold value, counts 4 fens.
1.3 statistical procedures method
Adopt SPSS11.5 software that data are carried out statistical analysis; All data are represented with
, are relatively checked with t between the enumeration data group.
2 results
2.1 occurred the decline of internal organs expansion toleration after the model group rat after juvenile stage is handled, grows up, can find out that scoring of model group AWR threshold value and physiology group (blank group) have the difference (P＜0.05) of statistical significance.After the treatment of rat after the modeling through positive drug (Trimebutine Maleate), the state of visceral hypersensitivity makes moderate progress, and has statistical significance (P＜0.05); Its AWR threshold value scoring under different pressures of 3 groups of Chinese medicine compositions of the present invention also all significantly is lower than model group (P＜0.05), and wherein the high dose group curative effect is the most obvious.The result sees table 1.
2.2 compare with model group, each proctectasia continues in the 3mi n, Chinese medicine composition high dose group of the present invention its stomach wall number of contractions under different pressures stimulates significantly reduces (P＜0.05), shows that visceral sensitivity reduces.The result sees table 2.
The AWR threshold value scoring of table 1 rat treatment back under different pressures stimulates relatively (divides
)
With the model group ratio,
*P＜0.05,
* *P＜0.001
The comparison (inferior,
) of table 2 rat treatment back abdominal muscle number of contractions under different pressures stimulates
With the model group ratio,
*P＜0.05,
* *P＜0.001
3 discuss
Visceral hypersensitivity (visceral hypersensitivity) is meant the susceptibility enhanced phenomenon of viscera tissue to stimulating; It is one of main pathogenesis of IBS; Also be the focus of studying at present, generally visceral sensitivity assessed through the capacity threshold or the pressure threshold that cause various sensations.
Duplicating of traditional I BS animal model; Have constraint braking stress, method such as chemical irritant induces, the electricity irritation limbs bring out; But model repeatability is relatively poor, and the paraesthesia of intestinal can disappear along with disappearing of inflammation, does not meet the chronic persistence process of patient's IBS stomachache or abdominal discomfort.And body receives peripheral sensitization at mezzanine level; Central sensitizationization forms chronic internal organs allergy easily; Based on this principle, the of short duration colon stimulations of discovery introduction stage such as AL Chaer can cause continuing to the chronic visceral hypersensitivity of manhood, and order does not have colon's pathological change; This visceral hypersensitivity model more can Simulation with I BS the long-term chronic course of disease, be more suitable for the research of IBS.
The mechanism of IBS internal organs sensitization is very complicated; Comprise cell and molecular pathology physiological process on a plurality of aspects of periphery and maincenter; Also there is bigger individual variation in IBS patient's clinical manifestation, has polytropy and repeatability, and therefore principle of individuation is generally followed in treatment; Take the comprehensive therapy measure, do not have a kind of medicine or monotherapy in full force and effect patient IBS.
Present embodiment shows; No matter be Chinese medicine composition high dose group of the present invention; Still in, low dose group, the AWR scoring of the high responsive rat of treatment back internal organs can obviously reduce, and shows that Chinese medicine composition of the present invention can obviously improve the threshold of feelings of the responsive rat of internal organs height to straight ectocolon; Confirming that this medicine has the effect that improves visceral sensitivity really, also possibly be one of Chinese medicine composition of the present invention mechanism of improving clinical IBS patient stomachache or abdominal discomfort symptom.And high dose group curative effect and Trimebutine Maleate are suitable, show relative chemical synthetic drug again, and Chinese medicine composition of the present invention has more safety, advantage efficiently.
The modern Chinese medicine pharmacological research confirms; Radix Rehmanniae Preparata, Semen Cuscutae ability mediator body immunity function, Rhizoma Coptidis has the effect that suppresses escherichia coli, aerobacteria and staphylococcus aureus, simultaneously the central nervous system is had sedation; Windproof have an anti-allergic effects, and Radix Paeoniae, Radix Glycyrrhizae can smooth muscle relaxings.And reuse Radix Paeoniae in the side and reach 30g; There is research to point out that the Chinese medicine Radix Paeoniae has dual regulation to IBS; Through prolongation total time-histories of interdigestive phase the dividing a word with a hyphen at the end of a line property period of motion, and the release of inhibition motilin discovers that in addition Radix Paeoniae Alba total glycosides can strengthen the colon shrinkage amplitude and regulate the colon motion.
Can there be periphery in visceral hypersensitivity, also can have maincenter.In recent years neural gastroenterology points out have brain intestinal axle to interconnect between central nervous system (CNS) and enteric nervous system (ENS), and wherein neurotransmitter such as 5-HT and IBS morbidity is closely related.5-HT has the intestinal of adjusting power, regulates functions [6] such as intestinal secretion and the perception of coordination intestinal.Camilleri etc. have confirmed that also the change of 5-HT running albumen (SERT) can influence the performance of IBS symptom; Think that SERT starts regional gene pleiomorphism and influenced the treatment of 5-HT3 antagonist to irritable bowel syndrome, 5-HT running GFP polymorphism maybe be relevant with the IBS hypotype.
We find that Chinese medicine composition of the present invention can treat IBS through improving the high sensitivity of internal organs really through present embodiment.
Claims (1)
1. Chinese medicine composition of treating irritable bowel syndrome is characterized by: this drug group become by weight, 100 parts of Radix Rehmanniae Preparata, 100 parts of Semen Cuscutae, 60 parts of Rhizoma Coptidis, 300 parts of Radix Paeoniaes, windproof 120 parts, 60 parts of Periostracum Cicadaes, 150 parts of Rhizoma Fagopyri Dibotryiss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103363802A CN102379970B (en) | 2011-10-31 | 2011-10-31 | TCM composition used for treating IBS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103363802A CN102379970B (en) | 2011-10-31 | 2011-10-31 | TCM composition used for treating IBS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102379970A true CN102379970A (en) | 2012-03-21 |
| CN102379970B CN102379970B (en) | 2013-02-27 |
Family
ID=45820070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103363802A Active CN102379970B (en) | 2011-10-31 | 2011-10-31 | TCM composition used for treating IBS |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102379970B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103830382A (en) * | 2014-02-24 | 2014-06-04 | 王学峰 | Traditional Chinese medicine composition for treating chronic diarrhea |
| CN106266329A (en) * | 2016-09-23 | 2017-01-04 | 四川金堂海纳生物医药技术研究所 | A kind of endo-medicine treating irritable bowel syndrome and preparation method thereof |
| CN109122563A (en) * | 2018-08-22 | 2019-01-04 | 江苏省中医药研究院 | A kind of modeling method of irritable bowel syndrome |
| CN112843143A (en) * | 2021-03-11 | 2021-05-28 | 河北省中医院 | Traditional Chinese medicine composition for treating constipation-predominant irritable bowel syndrome and medicament and application thereof |
-
2011
- 2011-10-31 CN CN2011103363802A patent/CN102379970B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 《中药学》 20030228 高学敏主编 金荞麦、蝉蜕 中国中医药出版社 第138－139页、第77-78页 1 , * |
| 《辽宁中医杂志》 20110131 陆敏、王德明 王德明以心肾不交论治肠易激综合征经验 第37页 1 第38卷, 第1期 * |
| 陆敏、王德明: "王德明以心肾不交论治肠易激综合征经验", 《辽宁中医杂志》 * |
| 高学敏主编: "《中药学》", 28 February 2003, 中国中医药出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103830382A (en) * | 2014-02-24 | 2014-06-04 | 王学峰 | Traditional Chinese medicine composition for treating chronic diarrhea |
| CN106266329A (en) * | 2016-09-23 | 2017-01-04 | 四川金堂海纳生物医药技术研究所 | A kind of endo-medicine treating irritable bowel syndrome and preparation method thereof |
| CN109122563A (en) * | 2018-08-22 | 2019-01-04 | 江苏省中医药研究院 | A kind of modeling method of irritable bowel syndrome |
| CN112843143A (en) * | 2021-03-11 | 2021-05-28 | 河北省中医院 | Traditional Chinese medicine composition for treating constipation-predominant irritable bowel syndrome and medicament and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102379970B (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100560126C (en) | A kind of Chinese medicine for oral administration that is used for the treatment of acne and preparation method thereof | |
| CN103877263B (en) | A kind of antifatigue health preparation of the compound Chinese medicine such as red ginseng, maca, green-tea extract (theanine) | |
| CN102379970B (en) | TCM composition used for treating IBS | |
| CN103860659A (en) | Traditional Chinese medicine for treating early nephrolith | |
| CN102641463A (en) | Traditional Chinese medicine composition for treating diarrhea-predominant irritable bowel syndrome | |
| CN105213738A (en) | A kind of Chinese medicine being used for the treatment of infantile constipation and preparation method thereof | |
| CN103860830A (en) | Traditional Chinese medicinal preparation for treating febrile convulsion and preparation method c | |
| CN102935106A (en) | Traditional Chinese medicine or food with function of regulating spleens, stomachs and intestines and preparation method and application thereof | |
| CN100382837C (en) | A medicine for treating children's excessive blink, hyperkinetic syndrome and Tottre's syndrome and method for preparing same | |
| CN103784665B (en) | Alleviate Chinese medicine preparation of irritable bowel syndrome and preparation method thereof | |
| CN103463456A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN108714172B (en) | Solid beverage for reducing fat and losing weight and preparation method thereof | |
| CN102526570B (en) | Foot bath Chinese medicinal composition for treating cough | |
| CN101314000B (en) | Gastrodia tuber eucommia health care capsule and preparation method thereof | |
| CN103830481A (en) | Medicine for treating recurrent respiratory tract infection of children | |
| CN103876207B (en) | Health soup for the treatment of tumor patient postoperative constipation and preparation method thereof | |
| CN102552423B (en) | Medicinal composition for treating migraine | |
| CN103230510A (en) | Medicament for treating bronchitis | |
| CN103721157B (en) | A kind of Chinese medicine preparation for the treatment of functional dyspepsia | |
| CN103877506A (en) | Medicament for treating epilepsy | |
| CN105796748A (en) | Medicine for treating infantile convulsion and preparation method thereof | |
| CN104800619A (en) | Traditional Chinese medicine for treating children nephrosis and preparation method of traditional Chinese medicine | |
| CN102309530B (en) | Pharmaceutical composition for treating or slowing inflammatory bowel disease | |
| CN104000902B (en) | Medicated wine of a kind of resisting fatigue and its preparation method and application | |
| CN1943654B (en) | A Chinese traditional medicinal composition and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 210028 No. 100 cross street, Nanjing, Jiangsu, Maigaoqiao Applicant after: Jiangsu Provincial Insititute of Traditional Chinese Medicine Address before: 210028, cross street, Hongshan Road, Jiangsu, Nanjing, 100 Applicant before: Jiangsu Provincial Insititute of Traditional Chinese Medicine |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER OWNER: JIANGSU PROVINCIAL INSITITUTE OF TRADITIONAL CHINESE MEDICINE Effective date: 20150610 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150610 Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 210028 No. 100 cross street, Nanjing, Jiangsu, Maigaoqiao Patentee before: Jiangsu Provincial Insititute of Traditional Chinese Medicine |
|
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address |